Category

Research
This article was originally published on UrbanhealthToday Insurance status was found to be significantly associated with survival for patients with multiple myeloma (MM), according to a study presented at the 2020 American Society of Hematology Annual Meeting & Exposition. Researchers analyzed data from the 2007-2016 Surveillance, Epidemiology, and End Results (SEER) Program database and identified 41,846 adults...
Continue Reading
This article was originally published on Curetoday The last 15 years have proved pivotal for patients with myeloma, as the Food and Drug Administration (FDA) has approved many active and highly specific therapies to treat the disease, according to Dr. Giada Bianchi. Bianchi, who is an associate director of the Amyloidosis Program at Brigham and...
Continue Reading
This article was originally published Cure There has been tremendous growth over the years in terms of treatment options for patients with multiple myeloma. That growth has extended to patients in the relapsed and refractory setting who often face an even more complex disease than patients with traditional multiple myeloma. This is as a result...
Continue Reading
This article was originally published on The limbic Subcutaneous daratumumab with pomalidomide and dexamethasone (D-Pd) is an effective and convenient treatment for patients with relapsed or refractory multiple myeloma who have received at least one line of therapy, including lenalidomide and a proteasome inhibitor. Speaking at the 62nd ASH Annual Meeting, Professor Meletios Dimopoulos presented...
Continue Reading
This article was originally published on Ash Clinical News Patients with relapsed/refractory multiple myeloma (MM) who were treated with a combination of subcutaneous daratumumab plus pomalidomide-dexamethasone (Pd) had a 37% lower risk of disease progression or death, compared with those who received Pd alone, according to results from the phase III APOLLO trial. Meletios Dimopoulos, MD, from...
Continue Reading
This article was originally posted on MEDpage Today Despite some concern over a novel ocular toxicity, the FDA granted accelerated approval to belantamab mafodotin (Blenrep) for heavily pretreated multiple myeloma following backing from an advisory panel, the first approved therapy that targets the B-cell maturation antigen (BCMA). Belantamab mafodotin is indicated for patients that have failed a...
Continue Reading
This article was originally published on Multiple Myeloma Today ABSTRACT BACKGROUND: Patients with hematological malignancies (HM), including multiple myeloma (MM), frequently suffer from immune deficiency-associated infectious complications because of both the disease and the treatment. Alarming results from China and the UK confirm the vulnerability of HM patients to severe acute respiratory syndrome coronavirus 2...
Continue Reading
This article was originally published on The Limbic Australian patients with multiple myeloma face critical shortcomings in genetic testing at diagnosis and access to new ‘standard of care’ treatments such as daratumumab, a leading haematologist has told a Parliamentary inquiry. Professor Andrew Spencer of Monash University says the current reimbursement model is unsuited to handling...
Continue Reading
This article was originally published on Cancer Network Results from a study presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting suggested that radiation therapy administered to patients with relapsed or refractory multiple myeloma awaiting CAR T-cells is safe and feasible without worsening rates of severe cytokine release syndrome (CRS), neurotoxicity, or hematologic...
Continue Reading
This article was originally published on Cancer Therapy Advisor As the coronavirus disease 2019 (COVID-19) pandemic evolves into subsequent waves in many parts of the world, there are many outstanding questions about the outcomes of infection for patients with multiple myeloma, specifically around the severity of outcomes, prognostic factors, and the effect of different treatments....
Continue Reading
1 2 3 4 5 6 8

Floor 7, 90 The Terrace
Wellington Central
New Zealand